Cargando…

Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility

Proton pump inhibitors (PPIs) have been increasingly used over the last decades and there are concerns about overuse and the numerous reported side-effects. It is uncertain whether associations between PPI use and potential side effects are causal. However, important evidence from experimental and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fossmark, Reidar, Martinsen, Tom C., Waldum, Helge L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829383/ https://www.ncbi.nlm.nih.gov/pubmed/31640115 http://dx.doi.org/10.3390/ijms20205203

Ejemplares similares

Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man
por: Waldum, Helge Lyder, et al.
Publicado: (2018)

The Phylogeny and Biological Function of Gastric Juice—Microbiological Consequences of Removing Gastric Acid
por: Martinsen, Tom C., et al.
Publicado: (2019)

Animal Models to Study the Role of Long-Term Hypergastrinemia in Gastric Carcinogenesis
por: Fossmark, Reidar, et al.
Publicado: (2011)

Gastritis, Gastric Polyps and Gastric Cancer
por: Waldum, Helge, et al.
Publicado: (2021)

Inflammation and Digestive Cancer
por: Waldum, Helge, et al.
Publicado: (2023)

Types of Gastric Carcinomas
por: Waldum, Helge L., et al.
Publicado: (2018)

Role of Autoimmune Gastritis in Gastric Cancer
por: Waldum, Helge L., et al.
Publicado: (2019)

Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified?
por: Fossmark, Reidar, et al.
Publicado: (2023)

Gastric Carcinomas Localized to the Cardia
por: Bakkelund, Karin E., et al.
Publicado: (2012)

Classification of tumours
por: Waldum, Helge L, et al.
Publicado: (2008)

Symptomatic Primary (AL) Amyloidosis of the Stomach and Duodenum
por: Fossmark, Reidar, et al.
Publicado: (2013)

Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
por: Aasarød, Kristin M., et al.
Publicado: (2021)

Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift
por: Waldum, Helge L., et al.
Publicado: (2018)

Expression of the Cholecystokinin-B Receptor in Neoplastic Gastric Cells
por: Mjønes, Patricia, et al.
Publicado: (2017)

Chronic diseases: what about infections of virus and prions via the gut?
por: Waldum, Helge, et al.
Publicado: (2021)

Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors
por: Maideen, Naina Mohamed Pakkir
Publicado: (2023)

Adverse Effects Associated with Proton Pump Inhibitor Use
por: Yibirin, Marcel, et al.
Publicado: (2021)

Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study
por: Fossmark, Reidar, et al.
Publicado: (2021)

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors
por: Yu, Li-Yuan, et al.
Publicado: (2017)

Proton Pump Inhibitors and the Risk of Adverse Cardiac Events
por: Juurlink, David N., et al.
Publicado: (2013)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective population‐based nested case‐control study
por: Ness‐Jensen, Eivind, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis
por: Boonpheng, Boonphiphop, et al.
Publicado: (2019)

Gastric Corpus Mucosal Hyperplasia and Neuroendocrine Cell Hyperplasia, but not Spasmolytic Polypeptide-Expressing Metaplasia, Is Prevented by a Gastrin Receptor Antagonist in H(+)/K(+)ATPase Beta Subunit Knockout Mice
por: Aasarød, Kristin Matre, et al.
Publicado: (2020)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Problems Associated with Deprescribing of Proton Pump Inhibitors
por: Helgadottir, Holmfridur, et al.
Publicado: (2019)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
por: Thong, Benjamin Ka Seng, et al.
Publicado: (2019)

Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence
por: Ben‐Eltriki, Mohamed, et al.
Publicado: (2020)

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011)

Adverse Effects of Proton Pump Inhibitors on Platelet Count: A Case Report and Review of the Literature
por: Mukherjee, Subhajit, et al.
Publicado: (2018)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Mechanisms of proton pump inhibitor‐induced hypomagnesemia
por: Gommers, Lisanne M. M., et al.
Publicado: (2022)

Proton pump inhibitors and dementia: what association?
por: Caetano, Catarina, et al.
Publicado: (2023)

Possible Effects of Proton Pump Inhibitors on Hearing Loss Development
por: Wiciński, Michał, et al.
Publicado: (2019)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010)

Proton pump inhibitors for the treatment of cancer in companion animals
por: Walsh, Megan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7s4tqds906ht782rj3lb7etkor